The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy

Duchesnay

Status and phase

Completed

Phase 3

Conditions

Nausea and Vomiting of Pregnancy

Treatments

Drug: Placebo

Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg

Study type

Interventional

Funder types

Industry

Identifiers

NCT00614445

DIC-301

Details and patient eligibility

About

The purpose of this study is to determine whether Diclectin® (doxylamine succinate USP 10 mg and pyridoxine HCl 10 mg) is more effective at controlling the nausea and vomiting of pregnancy than a placebo.

Full description

Nausea and vomiting of pregnancy (NVP), also known as "morning sickness," is a common condition that affects a large percentage of pregnant women. The symptoms can range from mild nausea to severe nausea and vomiting for which a woman may need to be hospitalized. Nausea and vomiting of pregnancy can affect a woman's quality of life and ability to conduct daily activities.

Diclectin® is a combination of 10 mg doxylamine succinate (an antihistamine), and 10 mg pyridoxine hydrochloride (vitamin B6) in a delayed release tablet formulation. It has been commercially available in Canada for the management of NVP for over 25 years and has been prescribed to over 33 million pregnant women.

Presently, there is no Food Drug and Administration (FDA) approved drug on the market to treat the symptoms of NVP. This study will test the efficacy of Diclectin® (doxylamine 10 mg, pyridoxine 10 mg in a delayed-release formulation) for NVP.

Patients enrolled in the study will receive between 2 and 4 tablets of Diclectin® or placebo daily, depending on their symptoms for up to 14 days. Patients will assess their symptoms of nausea and vomiting daily using a standardized questionnaire.

Enrollment

280 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

The patient has signed a written informed consent to participate in the study and has agreed to follow dosing instructions and complete all required study visits.
The patient is a pregnant female age equal to or greater than 18 years old.
The patient's entry ultrasound indicates a viable pregnancy and confirms gestational age of the fetus is 7-14 weeks at the anticipated time of the first dose of study medication or placebo. If an ultrasound was done within 4 weeks of the admission visit, and results can be obtained, an additional ultrasound is not necessary.
The patient is suffering from NVP and has a Pregnancy Unique Quantification of Emesis (PUQE) score ≥6.
The patient has not responded to conservative management consisting of dietary/lifestyle advice according to the 2004 ACOG Practice Bulletin.
The patient agrees, if on a multivitamin, to continue on their current dose of multivitamin for the duration of the trial.
The patient does not plan termination of the pregnancy.

Exclusion criteria

The investigator confirms the patient's nausea and vomiting is of etiology other than Nausea and Vomiting of Pregnancy (NVP).
The patient has gestational trophoblastic disease or multifetal gestation.
The patient has a condition for which antihistamines, in the opinion of the investigator, are contraindicated (epilepsy, alcoholism, glaucoma, chronic lung disease, urinary retention, heart block, etc.).
The patient has used antihistamines, anticholinergics, dopamine antagonists, serotonin antagonists, ginger, or anti-emetic therapy (including acupressure, acupuncture, homeopathic remedies, medical hypnosis, relief bands etc) to treat NVP in the previous 48 hours or plans to do so during the study .
The patient is using drugs that have anticholinergic activity (e.g., tricyclic antidepressants).
The patient is taking multivitamins containing more than 10 mg of vitamin B6, or plans to do so during the study.
The patient is taking supplementary vitamin B6 in addition to any multivitamin preparation, or plans to do so during the study.
The patient is currently drinking any amount of alcohol.
The patient has any condition that might interfere with the conduct of the study.
The patient is likely to be unable to comply with study procedures because of inadequate cognitive skills.
The patient has received an investigational drug within 30 days before enrollment in this study or is scheduled to receive an investigational drug during the course of this study.